Stage III Locally Advanced Pancreatic Cancer and Clinical Trials
With stage III Locally Advanced Pancreatic Cancer, most tumors are unresectable, which means they are unable to be removed by surgery. Common stage III treatment choices are chemotherapy, radiation or both, with or without clinical trials.
Clinical trials are the only way for researchers to see if new treatments help people with pancreatic cancer. The FDA looks at information from successful clinical trials to decide if an experimental treatment should be approved for a specific disease.
The 2020 National Comprehensive Cancer Network Guidelines for Locally Advanced Pancreatic Cancer Guidelines indicates pancreatic cancer patients who participate in clinical research may have better outcomes. Every treatment available today was approved through a clinical trial.
About the TIGeR-PaC Clinical Trial
The TIGeR-PaC Study is enrolling people with Locally Advanced Pancreatic Cancer who have recently been diagnosed. The goal is to determine whether an investigational method of delivering a routine anticancer drug, known as chemotherapy, with a device called RenovoCath®, can reduce the chance of the cancer spreading and extend survival, while improving quality of life.
Unlike other treatments that are given intravenously or into a vein (known as systemic chemotherapy), with RenovoCath the drug is delivered directly into the pancreas via an artery. This is known as intraarterial administration and involves the placement of a thin tube (called a catheter) into the artery via a small incision made in the leg or groin. There is evidence that delivering chemotherapy via an artery close to the tumor is an effective method for shrinking or stabilizing certain types of cancer. Studies have shown that gemcitabine delivered directly to the pancreatic arteries using RenovoCath may be associated with more than half the patients living over two years.IV